A phase II clinical trial on PD‐L1 inhibitors revealed that the objective response rate (ORR) was 12.2% among individuals with NSCLC and EGFR mutations who exhibited PD‐L1 expression in at least 25% of their tumor cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.